Regeneron Pharmaceuticals (WBO:REGN) Deferred Tax : €-776 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Regeneron Pharmaceuticals Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Regeneron Pharmaceuticals's change in deferred tax for the three months ended in Dec. 2023 was €-263 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2023 was €-776 Mil.

Regeneron Pharmaceuticals Deferred Tax Historical Data

The historical data trend for Regeneron Pharmaceuticals's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Deferred Tax Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Deferred Tax

Get a 7-Day Free Trial

-117.54

62.14

-130.18

-704.60

-768.26

Regeneron Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Deferred Tax	Get a 7-Day Free Trial															-264.04	-202.21	-193.18	-117.78	-262.54

Regeneron Pharmaceuticals Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-776 Mil.

Regeneron Pharmaceuticals Deferred Tax Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals (WBO:REGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (WBO:REGN) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico RGO:Germany REGN34:Brazil

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).